

REMARKS

Claims 1-7 and 9-27 currently appear in this application. The Office Action of June 6, 2008, has been carefully studied. These claims define novel and unobvious subject matter under Sections 102 and 103 of 35 U.S.C., and therefore should be allowed. Applicant respectfully requests favorable reconsideration, entry of the present amendment, and formal allowance of the claims.

Claim Objections

Claim 1 is objected to because of the spelling error on line 3.

The present amendment corrects this spelling error.

Rejections under 35 U.S.C. 112

Claims 1-7, 9-14, 21, 22 and 24-26 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner alleges that the term "perfluorocarbon" is indefinite.

This rejection is respectfully traversed. Submitted herewith is a list of the first 50 out of 1007 US patents in which the term "perfluorocarbon" appears in the claims. The Examiner's attention is also directed to US Patent 6,630,154,

issued by the Examiner's supervisor, Examiner James Wilson, that also includes the term "perfluorocarbon" in the claims. It is respectfully submitted that the term "perfluorocarbon" is not indefinite, and withdrawal of the rejection is respectfully solicited.

With respect to the correlation of the intended uses recited in claim 1, submitted herewith is an IDS citing a number of articles and abstracts in peer-review journals, published prior to the filing of the instant application, that correlate levels of nitric oxide or S-nitrosothiols, to a variety of disease or conditions. It should be noted that Alzheimer's disease is one of the conditions related to nitric oxide.

HELLP syndrome is an acronym for Hemolysis breakup of red blood cells (breakup of red blood cells), Elevated Liver Enzymes 9 a measure of liver damage and Low Platelets. This is a variety of preeclampsia, as shown in the attached printout from The Maternal and Child Health Forum.


The specification as filed provides guidance in administering perfluorocarbons for a variety of diseases and conditions, beginning at paragraph 0121 on page 43.

Appln. No. 10/663,693
Amd. dated December 1, 2008
Reply to Office Action of June 6, 2008

In view of the above, it is respectfully submitted
that the claims are now in condition for allowance, and
favorable action thereon is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Anne M. Kornbau
Registration No. 25,884

AMK:srd
Telephone No.: (202) 628-5197
G:\BN\N\NYUM\Nudler2A\PTO\2008-12-01Amendment.doc